Retrospective study shows improved outcomes in high-grade soft tissue sarcomas with doxorubicin, suggesting potential benefits.
In resectable, high-grade STS of 8 cm or more, single-agent doxorubicin as adjuvant chemotherapy showed a trend toward improved OS and DMFS compared with observation alone; however, statistical significance was not reached.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: